Estudo DELAY - Comunicado a participantes no estudo

DELAY of Appearance of sYmptoms of canine degenerative mitral valve disease treated with Spironolactone and Benazepril.

The DELAY study is a multi-centre clinical trial. The objective of this study is to investigate if treatment with Spironolactone and Benazepril is able to delay onset of clinical signs in dogs with asymptomatic mitral valve disease and cardiac enlargement.

Today, multicentre clinical trials represent the gold standard for investigating the effect of treatment on a disease. The two drugs tested in this study had been already approved for the treatment of dogs with this disease and heart failure. The DELAY wants to evaluate if starting the treatment earlier in the course of the disease is able to delay onset of clinical signs and in doing so prolong survival time and improve quality of life of the patients.

The study design is from the collaboration of an Italian group of cardiologists and the study protocol has been approved by the Italian Ministry of Health.
Estudo DELAY - Comunicado a participantes no estudo

The canine degenerative mitral valve disease (CDVD) is the most common disease of the dog and it is more frequent in the small size dogs, being more than 8 years old. 

Even if this disease has a benign course, the patients who present cardiac enlargement run a high risk to develop heart failure with consequent reduction in the quality and duration of life.

The scope of the treatment of the asymptomatic disease in dogs with cardiac enlargement, is to postpone the onset of the clinical signs and so to lengthen the period of very good quality of life of the dogs. 
The scope of the Delay Study is to evaluate the efficacy of the treatment with Spironolactone and Benazepril in deferring the onset of the clinical signs in dogs with asymptomatic CDVD and cardiac enlargement. The results of this trial will allow to optimize the treatment of this important cardio-vascular disease in the dog.
DELAY is a blind placebo used multicentric clinical trial. This type of study is considered – from  scientific point of view – the best one to evaluate the efficacy of a medical treatment. It is based on preliminary scientific data and the protocol has been approved by the Ministry of Health.
Both Spironolactone and Benazepril are drugs approved for the treatment of the CDVD combined with heart failure in the dog and have shown their efficacy and safety in the daily clinical practice.

The DELAY Study foresees the cooperation of 17 Italian veterinary centres with high professional qualification for the evaluation of the cardio-vascular diseases. The dogs involved in the study will be periodically carefully controlled in order to determine the disease progression.

All the enrolled dogs will take advantage of a highly qualified monitoring and you will always have available a Vet of reference for each possible problem you may have.

The DELAY is an important clinical trial. The results of this study will have positive consequences for thousands of patients as your dog. So, the participation of yr dog in this study can help many other dogs affected by the same problem.

In name of the DELAY Study Scientific Comittee - Dr. Michele Borgarelli, DVM, PhD, Diplomate ECVIM-CA (Cardiology)